Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Biomea Fusion, Inc.Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor AgonistCompany to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
- BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on October 10, 2026, under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in September 2026.
- Mental Health Screening Month: How Tech Is Fixing Therapy’s First-Month Dropout ProblemMental Health Screening Month: How Tech Is Fixing Therapy’s First-Month Dropout Problem Mon, 10/12/2026 - 15:35 Body Every week, millions of people sit down with their mental health therapy provider, take a deep breath, and try to answer a deceptively simple question: “So, how was your week?” For many, answering that question feels like trying to reconstruct a faded memory. The intense anxiety felt while sitting in traffic on Tuesday or the sudden wave of overwhelm on Thursday evening has lost its sharp edges by Monday morning. Clients often spend the first 15 minutes of a 50-minute appointment trying to recap past events rather than diving into meaningful healing work. This disconnect between weekly visits is a major contributor to a quiet crisis in mental healthcare: one in four clients discontinue psychotherapy, most after a single session. At the same time, the market has been flooded with thousands of standalone consumer wellness apps, with research showing that roughly 89% - 92% of mental health applications are abandoned by clients. The reason is simple: self-guided algorithms can’t replace the trust, empathy and safety of a human therapist. Image Why Do Standalone Apps Fail Where Clinician-Guided Tools Succeed? Unlike standalone apps that ask users to navigate their mental health journeys alone, next-generation platforms are designed to operate directly within existing clinical practices. By keeping the mental healthcare provider at the center of the care journey, technology transforms from a passive self-help tool into an active bridge between sessions. Exemplifying this shift is ReliefAI Health, a digital health venture created through LG NOVA (the North American Innovation Center for LG Electronics), exemplifies this shift. ReliefAI is built as a digital cognitive behavioral therapy (CBT) platform, for providers and clients. The mobile app enables clients to engage with their care plan daily and capture their mental state throughout their week. This gives providers the ability to understand what is going on with their clients at those crucial times to be better able to assess and support their clients through the therapy process. Rather than relying on paper notebooks or delayed memory, clients can use voice-journaling features while emotional experiences are still raw, work with interactive CBT exercises, complete clinical assessments and capture real-time mood patterns on their own schedule. How Does Between-Session Tracking Turn Passive Time Into Active Care? When technology integrates seamlessly into a clinic’s electronic health records system, the impact on care continuity is profound. "We see a crucial opportunity for technology to transform mental healthcare by strengthening the vital relationship between therapists and their clients," says the head of LG NOVA Sokwoo Rhee, Executive Vice President of Innovation at LG Electronics. "ReliefAI answers that need." Instead of starting an appointment with a blank slate, clinicians can review synthesized, objective data beforehand—observing mood trends, completed assessments and key themes from voice entries. Mental health providers begin the session already informed, bypassing routine recaps to focus immediately on deeper therapeutic progress. Rhee says this continuous model provides several distinct advantages for both clients and providers: Keeping clients connected to their therapeutic goals throughout the week can significantly reduce early dropout rates and help individuals stay committed through the critical first month. Tracking real-time insights that allow providers to tailor treatment plans dynamically and show clients tangible evidence of their growth over time. Remote therapeutic monitoring frameworks give practices structured clinical documentation and continuous engagement capabilities. What Does a Human-Centered Future for Mental Healthcare Look Like? As National Depression & Mental Health Screening Month highlights the growing demand for accessible, effective care, the narrative around digital health is evolving. The future of mental healthcare does not belong to standalone algorithms or automated substitutes for human connection, according to Rhee. Instead, the true breakthrough lies in next-generation platforms giving practitioners the data and visibility they need to do their best work, he says, adding: “By turning the days between sessions into an active, supported part of the healing process, clinician-guided technology can help assure that more people stay in care, build resilience and experience lasting well-being.” Featured Image Type of Content Article
- SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary DiseaseThe SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary...
- Glancy Prongay Wolke & Rotter LLPAardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitLOS ANGELES, Oct. 12, 2026/PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Aardvark Therapeutics, Inc. IF YOU SUFFERED A LOSS ON YOUR AARDVARK THERAPEUTICS, INC. INVESTMENTS,...
- UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & KorsinskyA securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verified through its own inspection
- LEAD TECH (Zhuhai) Electronic Co., Ltd.LEAD TECH Turns Booth LU-8931 into a Working Production Line at Pack Expo 2026, Demonstrating CIJ and UV Laser Coding on a Live Conveyor SystemThe Continuous Inkjet Printer and UV Laser Marking Machine Manufacturer Behind 70,000+ Global Installations Invites Food, Beverage, and Pharmaceutical Manufacturers to See Both Systems Run at Production Speed at Booth LU-8931, Chicago, October 18–21 CHICAGO, Oct. 12, 2026 --...
- Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway AnalysisMitoCareX expands its internal bioinformatics expertise to broaden the analysis of disease biology within its computational drug-discovery activities
- Accord BioPharmaAccord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF OptionsFILKRI is available with a permanent Q-code, standardizing the billing and reimbursement process across all sites of care. — Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology,...
- Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 development
- Ardelyx, Inc.Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-CAdditional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of life
- Bausch Health Companies Inc.Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical PathwayBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management...